Browsing Tag

#LB1148

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All…

Eli Pacheco Sep 15, 2022 0

CARLSBAD, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic…

Health

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study…

Eli Pacheco Aug 17, 2022 0

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic…

Health

Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference…

Eli Pacheco Mar 24, 2022 0

CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic…

Health

Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering…

Eli Pacheco Feb 18, 2022 0

CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic…

Health

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and…

Eli Pacheco Jun 15, 2021 0

CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI)…